alexa What are the Current Advances Regarding HIV Vaccines and HIV Vaccine Trials? | OMICS International
ISSN: 1948-593X
Journal of Bioanalysis & Biomedicine

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

What are the Current Advances Regarding HIV Vaccines and HIV Vaccine Trials?

Shayesta Dhalla*

University of British Columbia, Vancouver, British Columbia, Canada

*Corresponding Author:
Shayesta Dhalla
University of British Columbia, Vancouver
British Columbia, Canada
E-mail: [email protected]

Received Date: May 14, 2012; Accepted Date: May 14, 2012; Published Date: May 18, 2012

Citation: Dhalla S (2012) What are the Current Advances Regarding HIV Vaccines and HIV Vaccine Trials? J Bioanal Biomed 4:e106. doi:10.4172/1948-593X.1000e106

Copyright: © 2012 Dhalla S.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioanalysis & Biomedicine

Finding an HIV vaccine remains an elusive proposition. Thus far, there has been a paucity of HIV vaccine trials, and the majority have been unsuccessful with the vaccine showing no efficacy. A successful HIV vaccine can prevent HIV acquisition or slow down progression to AIDS.

HIV vaccine trials thus far in developed countries include the AIDSVAX B/B study and the STEP study (Americas, Caribbean, and Australia). The former study was unsuccessful. The STEP study was stopped in 2007, as it showed an increase in HIV infection for the first 18 months in uncircumcised men who had neutralizing antibodies to adenovirus-5 (Ad5) at baseline. A therapeutic HIV vaccine trial using HIV-immunogen (Remune) also showed the HIV vaccine was nonefficacious. In developing countries, HIV vaccine trials have included the AIDSVAX B/E study, the Phambili study (South Africa) and the RV144 study (Thailand). The Phambili study was halted after the STEP study results were available. Although the STEP study vaccine induced robust T-cell immune responses, it was not efficacious. Immune correlates were not established with these HIV vaccine studies.

The RV144 study using ALVAC-HIV (vCP1521) with AIDSVAX B/E boosting (VAXGen Env protein boost) in Thailand in low-risk heterosexuals showed a modest level of efficacy of the HIV vaccine (31.2%) (95% CI=1-51) after 3.5 years of vaccination but no effect on viral load. The efficacy at 12 months was 60%. The correlates of immune protection had not been yet established. The search for immune correlates secondary to the vaccine used was undertaken from 2010 to present. The case-control study demonstrated that the binding of IgG antibodies to variable region 1 and 2 (V1V2) of HIV-1 envelope proteins correlated inversely with the rate of HIV infection. The binding of plasma IgA antibodies to Env had a direct correlation with the rate of infection. This was hypothesis-generating in that vaccines developed to induce V1V2 antibodies and lower levels of Env-specific IgA antibodies may have improved efficacy against HIV infection. These IgA antibodies may have mitigated the effects of the protective antibodies. With regards to the results of the RV144 trial, recent advances have included the promise of structural biology for the design of novel envelope antigens. Recent work has also involved determining the structural biology of this V1V2 region.

HVTN 505 tests a combination of two experimental HIV vaccines (VRC vaccine): a DNA vaccine (priming vaccine) and a recombinant adenovirus vaccine (rAd5) (boosting vaccine). The study involves circumcised men who have sex with men, and who are adenovirus seronegative. HVTN 505 is a phase II, randomized, placebo-controlled, double-blind clinical trial, taking place in US cities. The study will (1) examine HIV acquisition (2) test whether the vaccine regimen can reduce viral load (3) provide safety information (4) provide more information on immune correlates (5) examine the interaction between pre-exposure prophylaxis (PrEP) and HIV vaccines.

The STEP study was stopped five years ago and the recent successful work on immune correlates may allow the field to proceed with more certainty. Further steps could include more proof-of-concept trials, adaptive trial designs, and more work on immune correlates. In further preventive trials, it may be more prudent to involve circumcised individuals.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12130
  • [From(publication date):
    June-2012 - Jun 21, 2018]
  • Breakdown by view type
  • HTML page views : 8336
  • PDF downloads : 3794

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7